KRAS + MTAP Loss Defines a Poor-Risk Pancreatic Cancer Subgroup: Clinical Cancer Research | June 2026

• This study highlights the importance of comprehensive genomic profiling in pancreatic adenocarcinoma, not only for identifying targetable alterations but also for defining biologically distinct prognostic subgroups.

• The analysis included a large pancreatic adenocarcinoma dataset, with more than 4,000 profiled samples and an additional 2,181-sample meta-cohort, making it a substantial genomic evaluation.

• Homozygous MTAP deletion was found in approximately 24% of pancreatic adenocarcinomas, confirming that MTAP loss is a common molecular event in this disease.

• Co-occurrence of KRAS mutation and MTAP loss was frequent, present in nearly 19% of all pancreatic adenocarcinomas.

• This co-mutated subgroup was associated with worse survival outcomes, suggesting that KRAS-mutant, MTAP-deficient pancreatic cancer represents a clinically aggressive phenotype.

• MTAP-deficient tumours showed a more fibrotic and immune-excluded tumour microenvironment, with less immune enrichment compared with MTAP-intact tumours.

• This is clinically relevant because pancreatic cancer is already characterized by dense stroma and poor immune infiltration; MTAP loss may further reinforce an immunologically resistant phenotype.

• Among KRAS-mutant, MTAP-deleted tumours, the most common KRAS variants were G12D, G12V, and G12R.

• KRAS G12R appeared to show slightly more immune-enriched tumour microenvironment features compared with other KRAS variants, suggesting that not all KRAS-mutant pancreatic cancers behave identically.

• The study supports the concept that KRAS mutation status alone is insufficient; co-alterations such as MTAP loss may better define prognosis, biology, and therapeutic vulnerability.

• MTAP loss may become increasingly important as investigational therapies targeting MTAP-deficient cancers, including synthetic-lethal strategies, continue to develop.

• For clinicians, the key message is that pancreatic cancer genomic profiling should include both driver mutations and copy-number alterations, because these can identify high-risk and potentially trial-eligible subgroups.

• This study does not immediately change standard treatment, but it strongly supports molecular stratification of pancreatic cancer for prognosis, trial design, and future targeted therapy development.

Bottom line: KRAS-mutant pancreatic adenocarcinoma with MTAP loss represents a common, aggressive, fibrotic, immune-excluded subgroup with poor prognosis, reinforcing the need for comprehensive genomic profiling and future MTAP-directed therapeutic strategies.